OrganiGram Holdings Inc.

TSX:OGI.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.96 -1.43%

-$0.02 today

Market cap
$135.37M
Beta
1.84
P/E (TTM)
-7.2
EPS (TTM)
-$0.19
52W Low $1.37High $3.09

Volume 0.54M

Average 0.19M

OGI.TO Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

OrganiGram Holdings Inc.TSX: OGI.TO

Depreciation & Amortization · Q2 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q2 FY2026 depreciation & amortization of CA$5.03M rose 4.0% year over year, behind the +37.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.1% from the prior quarter.

Context

  • Depreciation & amortization amounted to 6.9% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +4.0% toward the trailing-twelve-month pace of +37.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$5.03M+1.1% QoQ
Last fiscal yearSep 2025
CA$17.98M+48.8% YoY
LTMMar 2026
CA$19.76M+37.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.0%——
1 year+48.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

CAD · from the cash flow

Latest · FY2025
17.98M CAD
Year-over-year change
+48.8%
4-year CAGR
-12.8%

Depreciation & Amortization vs competitors

How OGI.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +37.8% is the 2nd highest of 10, against a peer median of -1.0%.
  • Depreciation & amortization amounts to 7.2% of revenue for OGI.TO, versus a peer median of 6.8%.
OGI.TO Competitors
Depreciation & Amortization for OGI.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$40.12M CAD-6.9%-23.0%12.9%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$21.99M USD-0.8%-13.6%39.4%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$19.76M CAD+37.8%—7.2%
TSND.TOTerrAscend Corp.LTM Mar 2026$16.25M USD-28.6%-9.8%6.2%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$14.19M CAD-37.1%-31.2%4.5%
DR.TOMedical Facilities CorporationLTM Mar 2026$13.77M USD-26.6%-9.0%4.5%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$11.86M CAD+14.9%-19.0%7.5%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$7.22M USD+30.0%+94.1%14.2%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$263.19K USD+45.4%+6.5%—
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$101.93K USD-1.0%—0.2%
Peer median (excluding OGI.TO) —-1.0%-11.7%6.8%

Competitors are the stored peer set for OGI.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Aug 2021
FY2022
Aug 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(130.7M)(14.28M)(229.48M)(45.44M)(24.76M)
Depreciation & Amortization31.03M24.91M24.17M12.08M17.98M
Deferred Income Tax42.21M(88K)(3.62M)0(13.77M)
Stock-Based Compensation3.9M5.13M5.29M7.18M4.22M
Change in Working Capital24.2M(22.88M)12.51M14.96M(2.12M)
Accounts Receivables(6.01M)(24.02M)12.51M(12.06M)(15.29M)
Inventory28.68M(12.22M)000
Accounts Payables2.06M12.15M000
Other Working Capital(542K)1.21M(5.52M)27.02M13.16M
Other Non-Cash Items776K(29M)155.33M15.09M12.47M
Operating Cash Flow(28.59M)(36.21M)(35.8M)3.87M(7.59M)
Capital Expenditures(12.33M)(48.78M)(26.9M)(5.34M)(17.05M)
Acquisitions (Net)(2.54M)(11.06M)1.03M257K(65.62M)
Purchases of Investments(120.02M)(15M)(10M)(29.24M)(1.01M)
Sales of Investments50.85M114.59M49.4M3.52M2.5M
Other Investing Activities(31.08M)4.29M(8.65M)(7.97M)(1.52M)
Investing Cash Flow(115.11M)44.03M1.36M(38.77M)(82.67M)
Debt Repayment(116.4M)(1.01M)(87K)(786K)(60K)
Common Stock Issued284.88M6.34M20K108.56M41.18M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.99M6.34M(750K)6K(1.79M)
Financing Cash Flow174.46M5.33M(817K)107.78M39.33M
Effect of Forex Changes0000313K
Net Change in Cash30.77M13.15M(34.65M)72.88M(49.01M)
Free Cash Flow(40.92M)(84.99M)(62.7M)(1.47M)(24.64M)

OrganiGram Holdings Inc.

TSX:OGI.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.